Literature DB >> 12018929

The current state of hormonal therapy for prostate cancer.

Beth A Hellerstedt1, Kenneth J Pienta.   

Abstract

Androgen deprivation therapy remains a mainstay of treatment for men with prostate cancer. New uses for hormonal therapy, including use in the adjuvant and neoadjuvant setting, are being evaluated. Prevention of the side effects of therapy has led to the development of alternative schedules and therapeutics.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12018929     DOI： 10.3322/canjclin.52.3.154

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN： 0007-9235            Impact factor:   508.702


  96 in total

1.  Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy.

Authors:  Makoto Sato; Mai Johnson; Liqun Zhang; Baohui Zhang; Kim Le; Sanjiv S Gambhir; Michael Carey; Lily Wu
Journal:  Mol Ther       Date:  2003-11       Impact factor: 11.454

2.  Goserelin versus leuprolide in the chemical castration of patients with prostate cancer.

Authors:  Élcio Dias Silva; Ubirajara Ferreira; Wagner Matheus; Eliney F Faria; Gustavo D Silva; Minori Saito; Auro A S de Souza; Azuil Laranjo; Otavio Clark; Luis Alberto Magna; Lísias Nogueira Castilho; Leonardo Oliveira Reis
Journal:  Int Urol Nephrol       Date:  2012-08       Impact factor: 2.370

3.  [How should hormone therapy for castration-resistant prostate cancer be continued?].

Authors:  M Spahn; M Krebs
Journal:  Urologe A       Date:  2012-01       Impact factor: 0.639

Review 4.  Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials.

Authors:  Dharam Kaushik; Vishal Vashistha; Sudhir Isharwal; Soud A Sediqe; Ming-Fong Lin
Journal:  Ther Adv Urol       Date:  2015-12

5.  Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer.

Authors:  Hui Gao; Xuesong Ouyang; Whitney A Banach-Petrosky; William L Gerald; Michael M Shen; Cory Abate-Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-14       Impact factor: 11.205

Review 6.  The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer.

Authors:  Jim N Rose; Juanita M Crook
Journal:  Ther Adv Urol       Date:  2015-06

Review 7.  Adaptation or selection--mechanisms of castration-resistant prostate cancer.

Authors:  Yang Zong; Andrew S Goldstein
Journal:  Nat Rev Urol       Date:  2012-12-18       Impact factor: 14.432

8.  Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues.

Authors:  Aditya Bagrodia; Christopher J Diblasio; Robert W Wake; Ithaar H Derweesh
Journal:  Indian J Urol       Date:  2009-04

9.  Increased expression of class III beta-tubulin in castration-resistant human prostate cancer.

Authors:  S Terry; G Ploussard; Y Allory; N Nicolaiew; F Boissière-Michot; P Maillé; L Kheuang; E Coppolani; A Ali; F Bibeau; S Culine; R Buttyan; A de la Taille; F Vacherot
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

10.  Integrin involvement in freeze resistance of androgen-insensitive prostate cancer.

Authors:  J G Baust; D P Klossner; R G Vanbuskirk; A A Gage; V Mouraviev; T J Polascik; J M Baust
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-01-12       Impact factor: 5.554
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.